Physician profile
Sam Kara
NPI 1932737764
$842.52
in general payments reported to CMS, 2019-2025
20 companies · $290 in 2025
The $290 reported for 2025 was more than what 75% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.71 · 2022: $106 · 2023: $195 · 2024: $163 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $200.97 | 2021-2025 | Briviact |
| Spr Therapeutics, INC | $102.58 | 2025 | Sprint Pns System |
| Horizon Therapeutics Plc | $83.01 | 2023 | Uplizna |
| Abbvie INC. | $69.18 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $43.26 | 2025 | Jornay Pm |
| Biogen, INC. | $41.93 | 2022 | |
| Atricure, INC. | $32.17 | 2023 | |
| Tg Therapeutics, INC. | $31.97 | 2024 | |
| Aquestive Therapeutics, INC. | $26.30 | 2025 | |
| Gilead Sciences, INC. | $25.40 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.30 | 2025 | Keveyis |
| Merz Pharmaceuticals, LLC | $22.99 | 2022 | |
| Sk Life Science, INC. | $22.58 | 2022 | |
| Saluda Medical Americas, INC. | $19.47 | 2025 | Evoke |
| Alnylam Pharmaceuticals INC. | $18.29 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.89 | 2023 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $16.59 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.38 | 2024 | Ultomiris |
| Neurocrine Biosciences, INC. | $15.16 | 2023 | Ongentys, Ingrezza |
| Emd Serono, INC. | $13.10 | 2023 | Mavenclad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Kara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.